Outpatient care for inflammatory bowel disease at a primary referral hospital in Turin

Minerva Gastroenterologica e Dietologica

Volumn 56, Issue 1, 2010, Pages 27-34

  Actis, G C ^a   Rosina, F ^a  

^a GRADENIGO HOSPITAL   (Italy)

Author keywords

Ambulatory care; Inflammatory bowel disease; Therapeutics

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISONE;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; BULIMIA; CHOLANGITIS; CLINICAL FEATURE; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; INFECTION; INSOMNIA; ITALY; JAUNDICE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOON FACE; NAUSEA; OUTPATIENT CARE; PANCREATITIS; PRIMARY MEDICAL CARE; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AMBULATORY CARE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; REFERRAL AND CONSULTATION;

EID: 77952375629     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657
2. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Medica Scand 1942;110:577-596
3. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006;533:2-14.
4. Rutgeerts P, Vermeire S, van Assche G. Biological therapies for inflammatory bowel disease. Gastroenterology 2009;136:1182-1197
5. Odes S. How expensive is inflammatory bowel disease. World J Gastroenterol 2008;14:6641-6647
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260
7. Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003;18:263-277
8. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962;49:592-593
9. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomized, double-blind study. N Engl J Med 1980;302:981-987 (Pubitemid 10125406)
10. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-22
11. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-489
12. Ben-Horin S, Goldstein I, Fudim E, Picard O, Yerushalmi Z, Barshack I et al. Early preservation of effector functions followed by eventual T-cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut 2009;58:396-403.
13. Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollon F. Meta-analysis : the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-137
14. Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E et al. Maintenance treatment with azathioprine in ulcerative colitis: out- come and predictive factors after drug withdrawal. Amer J Gastroenterol 2009;104:2760-2767
15. Actis GC, Pellicano R, David E, Sapino A. Azathioprine,mucosalhealing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets doi 10.2174/18712091 990601 15281.
16. Beaugerie L, Seksik P, Bouvier AM, Carbonnel F, Colombel JF, Faivre J et al. Study group for the CESAME. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with long-standing extensive colitis: results from the CESAME study. Gastroenterology 2009;5:A-54.
17. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J et al. on behalf of the CESAME study group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-1625
18. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-539
19. Actis GC, Pellicano R, Rizzetto M, Ayoubi M, Leone N, Tappero GF et al. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol 2009;15:1420-1426
20. Kirsch M. Physicians and Health-Care Reform: rolling up our sleeves or rolling the dice. Am J Gastroenterol 2009;104:1617-1619